Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure

COPENHAGEN, Denmark, Nov. 3, 2026 /PRNewswire/ -- Cambiotics ApS ("Cambiotics"), the company developing beneficial bacteria designed to support the natural elimination of unwanted compounds, such as per- and polyfluoroalkyl substances (PFAS, known as "forever chemicals"), announced today that the first participant has been enrolled in its first human clinical trial investigating its proprietary probiotic strain, 46-SL1, as a dietary supplement in firefighters with occupational exposure to PFAS. The study is a 2 x 12-week randomised, double-blind, placebo-controlled crossover trial, and it is being conducted by Atlantia Clinical Trials in Chicago, Illinois [NCT07846371].